Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16447201 | 1.00 | USP2 (0.40) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL2094040 | 1.00 | USP2 (0.40) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL1287846 | 0.98 | USP2 (0.39) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL3730156 | 0.98 | USP2 (0.37) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL30361807 | 0.92 | USP2 (0.37) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL28609548 | 0.86 | USP2 (0.31) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL29198910 | 0.83 | — | — | |
| SCHEMBL5497063 | 0.80 | USP2 (0.44) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL29973085 | 0.73 | CYP2C19 (0.42) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL3345554 | 0.72 | CYP2C19 (0.58) | USP2ALDH1A1LMNACYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 470 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119330937-B | Probe precursor for targeting CXCR4 receptor, probe, preparation method and application thereof | 山东大学 | 2025-04-25 | — | — | CN | claimed |
| US-20250057998-A1 | Radiopharmaceutical and Methods | Point Biopharma, Inc. | 2025-02-20 | — | — | US | claimed |
| CN-119330937-A | Probe precursor for targeting CXCR4 receptor, probe, preparation method and application thereof | 山东大学 | 2025-01-21 | — | — | CN | claimed |
| EP-4486397-A1 | RADIOPHARMACEUTICAL AND METHODS | Point Biopharma, Inc. (US) | 2025-01-08 | — | — | EP | claimed |
| CN-118878582-B | Marking precursor and probe for bone metastasis, and preparation method and application thereof | 山东大学 | 2025-01-03 | — | — | CN | claimed |
| WO-2023164769-A9 | RADIOPHARMACEUTICAL AND METHODS | Point Biopharma, Inc. (US) | 2024-11-07 | — | — | WO | claimed |
| CN-118878582-A | Marking precursor and probe for bone metastasis, and preparation method and application thereof | 山东大学 | 2024-11-01 | — | — | CN | claimed |
| WO-2024188291-A1 | HER2 TARGETED PEPTIDE AND USE THEREOF | 中国科学院上海药物研究所 | 2024-09-19 | — | — | WO | claimed |
| US-20240271184-A1 | LOW PH COMPOSITION AND METHOD FOR STABILIZING NUCLEIC ACIDS IN BIOLOGICAL SAMPLES | DNA GENOTEK INC. (CA) | 2024-08-15 | — | — | US | claimed |
| CN-118402016-A | Method for using and converting recovered radium | 埃克森美孚技术与工程公司 | 2024-07-26 | — | — | CN | claimed |
| EP-1399170-A2 | CHELATES OF METALS WHICH CAN BE ACTIVATED BY NEUTRONS AND THEIR USE FOR THE MEASUREMENT OF LABELED SPECIMENS | Biophysics Assay Laboratory, Inc. (US) | 2004-03-24 | — | — | EP | claimed |
| WO-2003104251-A9 | COMPOSITION AND METHODS FOR OBTAINING NUCLEIC ACIDS FROM SPUTUM | DNA GENOTEK INC (CA) | 2004-03-11 | — | — | WO | claimed |
| WO-2003104251-A2 | COMPOSITION AND METHODS FOR OBTAINING NUCLEIC ACIDS FROM SPUTUM | DNA GENOTEK INC. (CA) | 2003-12-18 | — | — | WO | claimed |
| US-20030198598-A1 | Polypeptide derivatives | ALBERT RAINER (CH) | 2003-10-23 | — | — | US | claimed |
| US-20030059368-A1 | Synthesis, compositions and methods for the measurement of the concentration of stable-isotope labeled compounds in life forms and life form excretory products | BIOPAL, INC. | 2003-03-27 | — | — | US | claimed |
| WO-2002062397-A2 | CHELATES OF METALS WHICH CAN BE ACTIVATED BY NEUTRONS AND THEIR USE FOR THE MEASUREMENT OF LABELED SPECIMENS | BIOPHYSICS ASSAY LABORATORY, INC. (US) | 2002-08-15 | — | — | WO | claimed |
| US-6409990-B1 | BACKBONE COMPRISING DEXTRAN HAVING AFFIXED THERETO A PLURALITY OF GROUPS HAVING AMINO-ALKYL-THIO-ALKYL-ETHER STRUCTURE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-06-25 | — | — | US | claimed |
| US-6193950-B1 | FOR DIAGNOSIS AND THERAPY | SCHERING AG (DE) | 2001-02-27 | — | — | US | claimed |
| EP-0436005-A1 | LABELED POLYPEPTIDE DERIVATIVES. | SANDOZ LTD (CH) | 1991-07-10 | — | — | EP | claimed |
| WO-1991001144-A1 | LABELED POLYPEPTIDE DERIVATIVES | SANDOZ LTD (CH) | 1991-02-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030198598-A1 | Polypeptide derivatives | HDGF, IGFBP1, VIP | USP2 3583/4885ALDH1A1 4768/4885LMNA 4029/4885 |
| US-20250057998-A1 | Radiopharmaceutical and Methods | KIT, PROKR1, LPXN | USP2 1919/4885ALDH1A1 3240/4885LMNA 1201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.